427 related articles for article (PubMed ID: 33736552)
1. Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment.
Hvas AM; Favaloro EJ; Hellfritzsch M
Expert Rev Hematol; 2021 Apr; 14(4):335-346. PubMed ID: 33736552
[No Abstract] [Full Text] [Related]
2. Potential Role of Direct Oral Anticoagulants in the Management of Heparin-induced Thrombocytopenia.
Barlow A; Barlow B; Reinaker T; Harris J
Pharmacotherapy; 2019 Aug; 39(8):837-853. PubMed ID: 31233222
[TBL] [Abstract][Full Text] [Related]
3. Novel fondaparinux protocol for anticoagulation therapy in adults with renal failure and suspected heparin-induced thrombocytopenia: a retrospective review of institutional protocol.
Ghaziri D; Dehaini H; Msheik M; Bahmad M; Zorkot M; Saad GA
BMC Pharmacol Toxicol; 2023 Jan; 24(1):2. PubMed ID: 36639796
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapy options in heparin-induced thrombocytopenia.
Chaudhary RK; Khanal N; Giri S; Pathak R; Bhatt VR
Cardiovasc Hematol Agents Med Chem; 2014; 12(1):50-8. PubMed ID: 25374012
[TBL] [Abstract][Full Text] [Related]
5. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.
Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Müller MM; Kropff S; Lindhoff-Last E
J Am Coll Cardiol; 2017 Nov; 70(21):2636-2648. PubMed ID: 29169470
[TBL] [Abstract][Full Text] [Related]
6. Emerging Role of Direct Oral Anticoagulants in the Management of Heparin-Induced Thrombocytopenia.
Tran PN; Tran MH
Clin Appl Thromb Hemost; 2018 Mar; 24(2):201-209. PubMed ID: 28301915
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban and apixaban for the treatment of suspected or confirmed heparin-induced thrombocytopenia.
Cirbus K; Simone P; Austin Szwak J
J Clin Pharm Ther; 2022 Jan; 47(1):112-118. PubMed ID: 34704283
[TBL] [Abstract][Full Text] [Related]
8. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review.
Warkentin TE; Pai M; Linkins LA
Blood; 2017 Aug; 130(9):1104-1113. PubMed ID: 28646118
[TBL] [Abstract][Full Text] [Related]
9. Heparin-induced thrombocytopenia treated with fondaparinux: single center experience.
Dulicek P; Ivanova E; Kostal M; Fiedlerova Z; Sadilek P; Hirmerova J
Int Angiol; 2020 Feb; 39(1):76-81. PubMed ID: 31782283
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting oral anticoagulants as emerging treatment options for heparin-induced thrombocytopenia.
Miyares MA; Davis KA
Ann Pharmacother; 2015 Jun; 49(6):735-9. PubMed ID: 25855702
[TBL] [Abstract][Full Text] [Related]
11. New developments in diagnosis and treatment of heparin-induced thrombocytopenia.
Lubenow N
Pathophysiol Haemost Thromb; 2003 Sep-2004 Dec; 33(5-6):407-12. PubMed ID: 15692252
[TBL] [Abstract][Full Text] [Related]
12. Direct acting oral anticoagulants for the treatment of suspected heparin-induced thrombocytopenia.
Davis KA; Davis DO
Eur J Haematol; 2017 Oct; 99(4):332-335. PubMed ID: 28672052
[TBL] [Abstract][Full Text] [Related]
13. Fondaparinux in a critically Ill patient with heparin-induced thrombocytopenia: A case report.
He Y; He H; Liu D; Long Y; Su L; Cheng W
Medicine (Baltimore); 2018 Sep; 97(37):e12236. PubMed ID: 30212955
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and management of heparin-induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group.
Joseph J; Rabbolini D; Enjeti AK; Favaloro E; Kopp MC; McRae S; Pasalic L; Tan CW; Ward CM; Chong BH
Med J Aust; 2019 Jun; 210(11):509-516. PubMed ID: 31155728
[TBL] [Abstract][Full Text] [Related]
15. Monitoring Fondaparinux in the Setting of Antithrombin Deficiency.
Staley EM; Simmons SC; Feldman AZ; Williams LA; Pham HP
Lab Med; 2019 Apr; 50(2):208-211. PubMed ID: 30169652
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia.
Tuleja A; Salvador D; Muka T; Bernhard S; Lenz A; Baumgartner I; Schindewolf M
Blood Adv; 2022 May; 6(10):3114-3125. PubMed ID: 35147675
[TBL] [Abstract][Full Text] [Related]
17. [Heparin-induced thrombocytopenia. New therapeutical options].
Seculini Patiño CE; Tabares AH
Medicina (B Aires); 2016; 76(4):230-4. PubMed ID: 27576282
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the use of direct oral anticoagulants for the management of heparin-induced thrombocytopenia.
Albuloushi A; Rhoten M; Kelly J; Sylvester KW; Grandoni J; Connors JM
J Thromb Thrombolysis; 2022 Nov; 54(4):597-604. PubMed ID: 36129561
[TBL] [Abstract][Full Text] [Related]
19. Fondaparinux as a treatment option for heparin-induced thrombocytopenia.
Papadopoulos S; Flynn JD; Lewis DA
Pharmacotherapy; 2007 Jun; 27(6):921-6. PubMed ID: 17542773
[TBL] [Abstract][Full Text] [Related]
20. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study.
Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Kropff S; Müller MM; Lindhoff-Last E
Thromb Res; 2014 Jul; 134(1):29-35. PubMed ID: 24703295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
